A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
© 2022. The Author(s)..
We investigated the safety and efficacy of nintedanib added to low-dose cytarabine (LDAC) in a phase 1/2 study in patients 60 years or older with newly diagnosed or relapsed/refractory (r/r) AML ineligible for intensive chemotherapy. The results of the dose-finding phase 1 part have been previously published. Patients were randomized 1:1 to LDAC plus nintedanib or LDAC plus placebo stratified by AML status (newly diagnosed vs r/r). LDAC was applied subcutaneously at 20 mg twice daily on days 1 to 10. Nintedanib/placebo was orally administered twice daily on days 1 to 28 in 28-day cycles. The primary endpoint was overall survival (OS). Between 05/2017 and 09/2019, 31 patients were randomized and 30 were treated, before the study was terminated prematurely due to slow recruitment. Median (range) age of patients was 76 (60-84) years. Twenty-two patients (73%) had r/r AML. Median OS in patients treated with LDAC and nintedanib was 3.4 months, compared with 3.6 months in those treated in the placebo arm, with a HR adjusted for AML status of 1.19 (corresponding confirmatory adjusted 95% CI, 0.55-2.56; univariate log-rank P = 0.96). In the 22 patients with r/r AML, median OS was 3.0 months in the nintedanib and 3.6 months in the placebo arm (P = 0.36). One patient in the nintedanib and two patients in the placebo arm achieved a CR and entered maintenance treatment. Nintedanib showed no superior therapeutic activity over placebo when added to LDAC in elderly AML patients considered unfit for intensive chemotherapy. The trial was registered at clinicaltrials.gov NCT01488344.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Annals of hematology - 102(2023), 1 vom: 02. Jan., Seite 63-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berdel, Andrew F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04079A1RDZ |
|---|
| Anmerkungen: |
Date Completed 04.01.2023 Date Revised 26.04.2023 published: Print-Electronic ClinicalTrials.gov: NCT01488344 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00277-022-05025-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349124310 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349124310 | ||
| 003 | DE-627 | ||
| 005 | 20231226041855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-022-05025-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349124310 | ||
| 035 | |a (NLM)36399194 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berdel, Andrew F |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2023 | ||
| 500 | |a Date Revised 26.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01488344 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a We investigated the safety and efficacy of nintedanib added to low-dose cytarabine (LDAC) in a phase 1/2 study in patients 60 years or older with newly diagnosed or relapsed/refractory (r/r) AML ineligible for intensive chemotherapy. The results of the dose-finding phase 1 part have been previously published. Patients were randomized 1:1 to LDAC plus nintedanib or LDAC plus placebo stratified by AML status (newly diagnosed vs r/r). LDAC was applied subcutaneously at 20 mg twice daily on days 1 to 10. Nintedanib/placebo was orally administered twice daily on days 1 to 28 in 28-day cycles. The primary endpoint was overall survival (OS). Between 05/2017 and 09/2019, 31 patients were randomized and 30 were treated, before the study was terminated prematurely due to slow recruitment. Median (range) age of patients was 76 (60-84) years. Twenty-two patients (73%) had r/r AML. Median OS in patients treated with LDAC and nintedanib was 3.4 months, compared with 3.6 months in those treated in the placebo arm, with a HR adjusted for AML status of 1.19 (corresponding confirmatory adjusted 95% CI, 0.55-2.56; univariate log-rank P = 0.96). In the 22 patients with r/r AML, median OS was 3.0 months in the nintedanib and 3.6 months in the placebo arm (P = 0.36). One patient in the nintedanib and two patients in the placebo arm achieved a CR and entered maintenance treatment. Nintedanib showed no superior therapeutic activity over placebo when added to LDAC in elderly AML patients considered unfit for intensive chemotherapy. The trial was registered at clinicaltrials.gov NCT01488344 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a Angiogenesis | |
| 650 | 4 | |a Low-dose cytarabine | |
| 650 | 4 | |a Nintedanib | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a nintedanib |2 NLM | |
| 650 | 7 | |a G6HRD2P839 |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 700 | 1 | |a Koch, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Gerss, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Hentrich, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Peceny, Rudolf |e verfasserin |4 aut | |
| 700 | 1 | |a Bartscht, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Steffen, Björn |e verfasserin |4 aut | |
| 700 | 1 | |a Bischoff, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |e verfasserin |4 aut | |
| 700 | 1 | |a Angenendt, Linus |e verfasserin |4 aut | |
| 700 | 1 | |a Mikesch, Jan-Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Kewitz, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Butterfass-Bahloul, Trude |e verfasserin |4 aut | |
| 700 | 1 | |a Serve, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Lenz, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Berdel, Wolfgang E |e verfasserin |4 aut | |
| 700 | 1 | |a Krug, Utz |e verfasserin |4 aut | |
| 700 | 1 | |a Schliemann, Christoph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 102(2023), 1 vom: 02. Jan., Seite 63-72 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2023 |g number:1 |g day:02 |g month:01 |g pages:63-72 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-022-05025-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2023 |e 1 |b 02 |c 01 |h 63-72 | ||